VistaGen Therapeutics Inc (VTGN)

[Johnny_C]

I think there will be catalysts to take money off the table at higher prices, where you could reduce your risk exposure.

The NIH study is just one, there is fast track designation, potential licensing agreements, the JP Morgan conference in January, new studies in other indications and the stem cell subsidiary that is in a partnership with a Bayer subsidiary.

Speaking of the stem cell component, one of the benefits is to pharma testing safety profiles in advance prior to expensive studies waste hundreds of millions of dollars. I am pretty sure AV-101 was put through these tests.

Again, Sage has no sales and popped up $75 or 2 billion in market cap on a phase 2 study